News BMS' Opdivo still streets ahead of Merck rival BMS to refocus operations, according to Q3 results.
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News Roche, Viking, and Syntis showcase obesity drug candidates A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
